Sino Biological's successful listing on the capital market is an important milestone in its strategic plan for growth. While justifying its current business model and portfolio, this offering also conveys a new starting point for the company’s future growth and development, providing the financial backing for broad and rapid expansion of Sino Biological’s existing capabilities. Dr. Liangzhi Xie, Chairman of Sino Biological, expressed in his speech at the listing ceremony that, through this offering, “Sino Biological will now be able to further enhance its strength in as one of the world’s leading providers of research reagents and services, while simultaneously improving its competitiveness and profitability. These endeavors will bring multiple benefits to investors such as increased shareholder value while positively impacting the health and well-being of society.”
The Listing Ceremony
As a high-tech enterprise, Sino Biological specializes in the research, development, production and sales of biological reagents such as ...
